Bristol-myers Company

Bristol-myers Squibb Compnay

Other

Takeo Miyaki

Masataka Konishi

Toshikazu Oki

Hiroshi Kawaguchi

Maki Nishio

Mitsuaki Tsunakawa

Koji Tomita

Yosuke Sawada

Kyoichiro Saitoh

Osamu Tenmyo

Masaru Ohbayashi

Masatoshi Kakushima

Koko Sugawara

Masami Hatori

Keiko Shimizu

Kozo Tomatsu

Hiroaki Ohkuma

Hiroshi Tsukiura

Takashi Tsuno

Fumihide Sakai

Haruaki Yamamoto

Shigeyuki Ando

Nahomi Oda

The present invention relates to novel antifungal antibiotics herein designated as pradimicin L and pradimicin FL, and derivatives thereof. Pradimicins L and FL are produced by Actinomadura verrucosospora subsp. neohibisca strain R103-3, ATCC No. 53930.

Pradimicins l and fl, and derivatives thereof

Production of an antiviral antibiotic complex, BU-3889V and its bioactive components A.sub.1, A.sub.2, A.sub.3, D.sub.1, D.sub.2 and D.sub.3, by fermentation of a BU-3889V producing strain of the new microorganism Amycolatopsis orientalis ATCC-53884 is disclosed. Complex BU-3889V is recovered and the components separated by the use of ion exchange chromatography techniques. The bioactive components are characterized by their physico-chemical characterizing properties. The products have been found to be effective to inhibit viruses including herpes simplex virus, human immunodeficiency virus (HIV) and influenza virus.

Antiviral antibiotic BU-3889V

Disclosed are antibiotics BU-3608 FA-1 and FA-2 and alkyl derivatives thereof. These compounds are useful as antifungal agents. BU-3608 FA-1 and FA-2 are produced from Actinomadura hibisca in a medium containing a source of D-serine.

Method for treating fungal infections with serine analogs of BU-3608

The novel antitumor antibiotic designated herein as dynemicin C is produced by fermentation of Micromonospora chersina M956-1 mutant F1085 (ATCC-55077). Dynemicin C and its triacetate derivative possess antibacterial and antifungal activity and also inhibit the growth of mammalian tumors.

Dynemicin C antibiotic, its triacetyl derivative and pharmaceutical

Process for preparing antiviral antibiotic BU-3889V

Actinomadura hibisca microorganism useful for preparing serine analogs

Novel antibiotic herein designated as BU-3608, BU-3608 B, and BU-3608 C are produced by fermentation of Actinomadura hibisca Strain No. P157-2, ATCC 53557, and Strain No. Q278-4, ATCC 53646. The antibiotics possess antifungal and antiviral activities.

Antifungal antibiotics

Disclosed herein are antibiotic BU-3608 D and E isolated from Actinomadura hibisca. These compounds are active antifungal agents.

Process for producing antibiotics BU-3608 D and BU-3608 E

Serine analogs of BU-3608 antibiotics

A novel antibiotic designated BU-4146T is produced by fermentation of Streptomyces amphibiosporus strain R310-104 (ATCC-53964). The antibiotic possesses both antifungal and antitumor activity.

BU-4146T antibiotic

A new antibiotic having the chromophore structure of the plurmycin family of antibiotics is produced by fermentation of Streptomyces violaceus ATCC 53807. The new antibiotic designated BU-3839T, exhibits potent antibacterial activity and also inhibits the growth of tumors in experimental animal systems.

BU-3839T antibiotic

Antibiotics BU-3608D and BU-3608E

An new antibiotic having the chromophore structure of the pluramycin family of antibiotics is produced by fermentation of Streptomyces violaceus ATCC 53807. The new antibiotic designated BU-3839T, exhibits potent antibacterial activity and also inhibits the growth of tumors in experimental animal systems.

Biological pure culture of Streptomyces violaceus ATCC 53807

Growing community of inventors

Yokohama, Japan

Takeo Miyaki